Amgen

We are all different, yet we have this in common: our mission to serve patients. This sense of shared purpose is key to our becoming one of the world’s leading biotechnology companies. It guides us as we continue to launch new medicines and reach millions of patients worldwide.

We live the mission.

We win together.

We thrive on continual challenge.

Our team of 27,000+ scientists and professionals worldwide bring distinct perspectives and experiences to all we do. We leverage our global talent to achieve together—to research, manufacture and deliver ever-better products and greater depth to our mission.

At Amgen, there is a strong correlation between our high level of diversity and performance. Because addressing issues with a wider range of perspectives and approaches leads to more creative problem-solving. Together, we’re transforming the promise of science and biotechnology into therapies that have the power to restore health.

Connect with us to explore how you can Win, Live, and Thrive at Amgen.

AWARDS
  • 2025 BPTW Badge - RBG.png
  • 2024 Best Places to Work
  • 2023 Best Places to Work
  • 2022 Best Places to Work
  • amgen forbes award.png
  • amgen fortune award.png
  • amgen innovative award.png
  • amgen diversity award.png
Corporate Headquarters
One Amgen Center Drive
Thousand Oaks, CA 91320
  • Featured Employer Badge
We know an idea—any idea—can blossom into a lifesaving treatment. That’s why we dare to ask the questions most people won’t. Join us in pushing biotechnology.
Employee Testimonials
  • “Amgen fosters a culture of innovation, with a science-based risk approach, centered in the benefit of our patients and powered by the diversity of our staff.”
    Jorge D.
    Porcess Scientific Director
    Juncos, PR
  • “Cultivate your curiosity and continue to learn at Amgen — grow daily and explore career opportunities that align with your competencies and motivation”
    Fernando F.
    Executive Director Plant Manager
    Rhode Island, US
  • “Working at Amgen, as Specialist Quality Control gives me the opportunity to work with Amgen products in benefit of the patients. Using my knowledge in science and share my diversity with my peers, is the best experience I have as part of the Amgen family.”
    Niria R.
    Specialist Quality Control
    Juncos, PR
Serving patients across the globe requires a global team. We continue building a diverse workforce that reflects the needs of those they serve, bringing with them innovative ideas that can push biotechnology forward.
We offer more than benefits. Our Total Rewards Program secures the long-term financial, physical and overall well-being of you and your family. Among leading biotechnology and pharmaceutical leaders, we stand among the very best.
Through Amgen Volunteers, you can dedicate eight hours to participating organizations of your choice. This along with matching employee donations to charities and our diverse corporate giving initiatives are just some ways you can make meaningful contributions as a global citizen
Amgen is proud of the achievements we have realized as a mission-driven team—particularly the accolades we have earned as an employer. You can find our teams named in respected lists including Forbes, Fast Company and more.
NEWS
Janssen (Johnson & Johnson) is no longer in the running to acquire rare disease player Horizon Therapeutics, the company announced Saturday. This leaves Amgen and Sanofi at the bidding table.
BioSpace’s 2023 “Best Places to Work,” highlights innovative companies with a positive workplace culture, flexibility and strong leadership.
Amgen opened a new research and development site in San Francisco Bay, while Enzo Biochem opened a 100,000 square foot laboratory and research facility in New York
Merck announced positive results on its patent infringement case against Viatris, while Amgen faces political headwinds from the White House.
NSCLC At ESMO: Pollution does indeed cause lung cancer; Tecentriq shows promise in poor prognosis patients, Amgen makes progress in KRAS G12-mutated disease and an update on a Daiichi Sankyo ADC.
Amgen presented data from its Phase III CodeBreaK 200 trial of Lumakras showing the drug improved progression-free survival and objective response rate over intravenous chemotherapy.
Amgen announced Tuesday that initial Phase III data of Lumakras in KRAS G12C-mutated NSCLC met the primary endpoint of progression-free survival.
Finding a job right out of college can seem like a daunting task. To help, BioSpace has compiled a list of the top companies hiring new grads for entry-level roles.
Amgen announced two lung cancer studies with mixed results, Innovent dosed the first patient in a Phase I diabetic macular edema study and HUTCHMED hit the primary endpoint in colorectal cancer.
JOBS
IN THE PRESS